Nothing said here yet.
to join the conversation.
| BORGESON JOHN A.Chief Financial Officer | Sell | 8,514 | $746.4K | Wed, Oct 21 |
| BORGESON JOHN A.Chief Financial Officer | Sell | 7,623 | $684.1K | Wed, Oct 21 |
| BORGESON JOHN A.Chief Financial Officer | Sell | 5,101 | $464.1K | Wed, Oct 21 |
| BORGESON JOHN A.Chief Financial Officer | Sell | 2,985 | $273.9K | Wed, Oct 21 |
| BORGESON JOHN A.Chief Financial Officer | Sell | 2,000 | $187.4K | Wed, Oct 21 |
| BORGESON JOHN A.Chief Financial Officer | Sell | 2,000 | $185.3K | Wed, Oct 21 |
| BORGESON JOHN A.Chief Financial Officer | Sell | 1,677 | $149.6K | Wed, Oct 21 |
| BORGESON JOHN A.Chief Financial Officer | Sell | 100 | $9.5K | Wed, Oct 21 |
| BAKER BROS. ADVISORS LPDirector | Buy | 20,031 | $1.7M | Tue, Sep 29 |
| BAKER BROS. ADVISORS LPDirector | Buy | 10,381 | $874.5K | Tue, Sep 29 |
| BAKER BROS. ADVISORS LPDirector | Buy | 1,416 | $121.6K | Tue, Sep 29 |
| BAKER BROS. ADVISORS LPDirector | Buy | 1,195 | $102.1K | Tue, Sep 29 |
Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.
Kodiak Sciences (KOD) is back in focus after fresh clinical news. The company plans to showcase late stage data for Zenkuda, tabirafusp ted and KSI 101 at AAO 2026 in New Orleans.
Kodiak Sciences has delivered an extremely strong multi year share price run, which naturally raises a simple question for anyone looking at the chart today.
Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical…
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
Kodiak Sciences reported strong endpoint results for its late-stage eye injection candidate, sending its stock soaring.
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.